Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2121-2130 Newer>

The Motley Fool June 24, 2005 Brian Gorman	Salix's Strange Deal Salix announced that it will buy Inkine in an all-stock acquisition valued at $190 million. At first glance, the two companies appear to be a good strategic fit, since both specialize in marketing gastrointestinal drugs. However, the agreement seems to have more weaknesses than strengths.
The Motley Fool June 23, 2005 Bill Barker	History Is Made, for Now At yesterday's annual meeting, Flamel's shareholders made history. All proposals to re-elect the former directors were rejected by voting shareholders.
The Motley Fool June 23, 2005 Brian Gorman	Amgen's Drug-Approval Dilemma A recent lawsuit illustrates drugmakers' difficult position. Even conservative drug-stock investors could be in for a bumpy ride.
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull Rebuttal Priced at a P/E of 13 and paying you a 4.8% dividend, Merck isn't just affordable -- it's a stock you can't afford not to own.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Rebuttal There's a reason why Merck's stock is cheap: weak pipeline, weak prospects.
The Motley Fool June 23, 2005 Stephen D. Simpson	Dueling Fools: Merck Bear Looking at other big pharma peers, Merck is dead last when it comes to expected three- to five-year EPS growth. Why buy a troubled pharma when better options exist?
The Motley Fool June 23, 2005 Rich Smith	Dueling Fools: Merck Bull It's hard to argue with a price this cheap. With a price-to-free cash flow ratio of less than 11, Merck's a steal.
The Motley Fool June 22, 2005 Brian Gorman	Biotech's Global Agenda Bristol-Myers' recent outsourcing deal illustrates the global spread of biotech investments.
The Motley Fool June 22, 2005 Stephen D. Simpson	Stent Wars: Jury Strikes Back A jury finds that Boston Scientific has violated J&J's stent patents, but the battle is only beginning. Meanwhile, Boston Scientific continues to have market-share leadership in drug-coated stents and makes quite a bit of money from it.
The Motley Fool June 21, 2005 Charly Travers	A Biotech Bargain Paying $1.6 billion for a robust pipeline and promising future may be a steal. Purchasing Transkaryotic's drug portfolio should pay off very soon for the specialty pharmaceutical Shire.
<Older 2121-2130 Newer> Return to current articles.